Oral administration of Bifidobacterium breve B-3 modifies metabolic functions in adults with obese tendencies in a randomised controlled trial
Accumulating evidence suggests an association between gut microbiota and the development of obesity, raising the possibility of probiotic administration as a therapeutic approach. Bifidobacterium breve B-3 was found to exhibit an anti-obesity effect on high-fat diet-induced obesity mice. In the pres...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cambridge University Press
2015-01-01
|
| Series: | Journal of Nutritional Science |
| Subjects: | |
| Online Access: | https://www.cambridge.org/core/product/identifier/S2048679015000051/type/journal_article |
| _version_ | 1811155988990918656 |
|---|---|
| author | Jun-ichi Minami Shizuki Kondo Naotake Yanagisawa Toshitaka Odamaki Jin-zhong Xiao Fumiaki Abe Shigeru Nakajima Yukie Hamamoto Sanae Saitoh Taeko Shimoda |
| author_facet | Jun-ichi Minami Shizuki Kondo Naotake Yanagisawa Toshitaka Odamaki Jin-zhong Xiao Fumiaki Abe Shigeru Nakajima Yukie Hamamoto Sanae Saitoh Taeko Shimoda |
| author_sort | Jun-ichi Minami |
| collection | DOAJ |
| description | Accumulating evidence suggests an association between gut microbiota and the development of obesity, raising the possibility of probiotic administration as a therapeutic approach. Bifidobacterium breve B-3 was found to exhibit an anti-obesity effect on high-fat diet-induced obesity mice. In the present study, a randomised, double-blind, placebo-controlled trial was conducted to evaluate the effect of the consumption of B. breve B-3 on body compositions and blood parameters in adults with a tendency for obesity. After a 4-week run-in period, the participants were randomised to receive either placebo or a B-3 capsule (approximately 5 × 1010 colony-forming units of B-3/d) daily for 12 weeks. A significantly lowered fat mass was observed in the B-3 group compared with the placebo group at week 12. Improvements were observed for some blood parameters related to liver functions and inflammation, such as γ-glutamyltranspeptidase and high-sensitivity C-reactive protein. Significant correlations were found between the changed values of some blood parameters and the changed fat mass in the B-3 group. These results suggest the beneficial potential of B. breve B-3 in improving metabolic disorders. |
| first_indexed | 2024-04-10T04:44:01Z |
| format | Article |
| id | doaj.art-6aed81b7527945308d380649909fe0e3 |
| institution | Directory Open Access Journal |
| issn | 2048-6790 |
| language | English |
| last_indexed | 2024-04-10T04:44:01Z |
| publishDate | 2015-01-01 |
| publisher | Cambridge University Press |
| record_format | Article |
| series | Journal of Nutritional Science |
| spelling | doaj.art-6aed81b7527945308d380649909fe0e32023-03-09T12:38:43ZengCambridge University PressJournal of Nutritional Science2048-67902015-01-01410.1017/jns.2015.5Oral administration of Bifidobacterium breve B-3 modifies metabolic functions in adults with obese tendencies in a randomised controlled trialJun-ichi Minami0Shizuki Kondo1Naotake Yanagisawa2Toshitaka Odamaki3Jin-zhong Xiao4Fumiaki Abe5Shigeru Nakajima6Yukie Hamamoto7Sanae Saitoh8Taeko Shimoda9Food Science and Technology Institute, Morinaga Milk Industry Co. Ltd, Zama, Kanagawa, JapanFood Science and Technology Institute, Morinaga Milk Industry Co. Ltd, Zama, Kanagawa, JapanNutritional Science Institute, Morinaga Milk Industry Co. Ltd, Zama, Kanagawa, JapanFood Science and Technology Institute, Morinaga Milk Industry Co. Ltd, Zama, Kanagawa, JapanFood Science and Technology Institute, Morinaga Milk Industry Co. Ltd, Zama, Kanagawa, JapanFood Science and Technology Institute, Morinaga Milk Industry Co. Ltd, Zama, Kanagawa, JapanNAKAJIMA Medical Clinic, Yokosuka, Kanagawa, JapanNAKAJIMA Medical Clinic, Yokosuka, Kanagawa, JapanDivision of Healthcare Graduate School, Tokyo Healthcare University, Setagaya, Tokyo, JapanDivision of Healthcare Graduate School, Tokyo Healthcare University, Setagaya, Tokyo, JapanAccumulating evidence suggests an association between gut microbiota and the development of obesity, raising the possibility of probiotic administration as a therapeutic approach. Bifidobacterium breve B-3 was found to exhibit an anti-obesity effect on high-fat diet-induced obesity mice. In the present study, a randomised, double-blind, placebo-controlled trial was conducted to evaluate the effect of the consumption of B. breve B-3 on body compositions and blood parameters in adults with a tendency for obesity. After a 4-week run-in period, the participants were randomised to receive either placebo or a B-3 capsule (approximately 5 × 1010 colony-forming units of B-3/d) daily for 12 weeks. A significantly lowered fat mass was observed in the B-3 group compared with the placebo group at week 12. Improvements were observed for some blood parameters related to liver functions and inflammation, such as γ-glutamyltranspeptidase and high-sensitivity C-reactive protein. Significant correlations were found between the changed values of some blood parameters and the changed fat mass in the B-3 group. These results suggest the beneficial potential of B. breve B-3 in improving metabolic disorders.https://www.cambridge.org/core/product/identifier/S2048679015000051/type/journal_article Bifidobacterium Metabolic syndromeObesityRandomised controlled trials |
| spellingShingle | Jun-ichi Minami Shizuki Kondo Naotake Yanagisawa Toshitaka Odamaki Jin-zhong Xiao Fumiaki Abe Shigeru Nakajima Yukie Hamamoto Sanae Saitoh Taeko Shimoda Oral administration of Bifidobacterium breve B-3 modifies metabolic functions in adults with obese tendencies in a randomised controlled trial Journal of Nutritional Science Bifidobacterium Metabolic syndrome Obesity Randomised controlled trials |
| title | Oral administration of Bifidobacterium breve B-3 modifies metabolic functions in adults with obese tendencies in a randomised controlled trial |
| title_full | Oral administration of Bifidobacterium breve B-3 modifies metabolic functions in adults with obese tendencies in a randomised controlled trial |
| title_fullStr | Oral administration of Bifidobacterium breve B-3 modifies metabolic functions in adults with obese tendencies in a randomised controlled trial |
| title_full_unstemmed | Oral administration of Bifidobacterium breve B-3 modifies metabolic functions in adults with obese tendencies in a randomised controlled trial |
| title_short | Oral administration of Bifidobacterium breve B-3 modifies metabolic functions in adults with obese tendencies in a randomised controlled trial |
| title_sort | oral administration of bifidobacterium breve b 3 modifies metabolic functions in adults with obese tendencies in a randomised controlled trial |
| topic | Bifidobacterium Metabolic syndrome Obesity Randomised controlled trials |
| url | https://www.cambridge.org/core/product/identifier/S2048679015000051/type/journal_article |
| work_keys_str_mv | AT junichiminami oraladministrationofbifidobacteriumbreveb3modifiesmetabolicfunctionsinadultswithobesetendenciesinarandomisedcontrolledtrial AT shizukikondo oraladministrationofbifidobacteriumbreveb3modifiesmetabolicfunctionsinadultswithobesetendenciesinarandomisedcontrolledtrial AT naotakeyanagisawa oraladministrationofbifidobacteriumbreveb3modifiesmetabolicfunctionsinadultswithobesetendenciesinarandomisedcontrolledtrial AT toshitakaodamaki oraladministrationofbifidobacteriumbreveb3modifiesmetabolicfunctionsinadultswithobesetendenciesinarandomisedcontrolledtrial AT jinzhongxiao oraladministrationofbifidobacteriumbreveb3modifiesmetabolicfunctionsinadultswithobesetendenciesinarandomisedcontrolledtrial AT fumiakiabe oraladministrationofbifidobacteriumbreveb3modifiesmetabolicfunctionsinadultswithobesetendenciesinarandomisedcontrolledtrial AT shigerunakajima oraladministrationofbifidobacteriumbreveb3modifiesmetabolicfunctionsinadultswithobesetendenciesinarandomisedcontrolledtrial AT yukiehamamoto oraladministrationofbifidobacteriumbreveb3modifiesmetabolicfunctionsinadultswithobesetendenciesinarandomisedcontrolledtrial AT sanaesaitoh oraladministrationofbifidobacteriumbreveb3modifiesmetabolicfunctionsinadultswithobesetendenciesinarandomisedcontrolledtrial AT taekoshimoda oraladministrationofbifidobacteriumbreveb3modifiesmetabolicfunctionsinadultswithobesetendenciesinarandomisedcontrolledtrial |